Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool January 7, 2005 Brian Gorman	Canadian Drug Sales Might End Drug makers may not have to worry about cheap pills flooding into the U.S. from across the border, at least for now, offering a small consolation to investors.
The Motley Fool September 10, 2004 Charly Travers	Looming Drug Shortages The push for drug re-importation into the U.S. will have consequences abroad. With supply restrictions in place, Canada and the U.K. are at a higher risk of drug shortages if pharmacies in those countries continue to sell drugs to U.S. citizens.
Managed Care May 2000 Bob Carlson	Northeast States Pursue Price Controls To Stop Rise in Prescription Drug Costs "The high cost of prescription drugs is a crisis," says Maine Senate Majority Leader Chellie Pingree. "Working people tell us they make a difficult choice between filling their prescription or buying food or heating oil -- or, in many cases, going broke....
The Motley Fool September 9, 2009 Brian Orelli	Don't Like High Drug Costs? Blame Canada. Through a combination of price controls instituted by the Patented Medicine Prices Review Board, and through government negotiations, Canada is able to keep its drug costs down for its citizens. But that doesn't make it right.
The Motley Fool March 15, 2004 W.D. Crotty	60 Minutes on Drugs Will the weekly news magazine's prime-time slam rattle the drug stocks?
The Motley Fool August 6, 2007 Brian Orelli	Cheap Drugs on the Farm The House approves a prescription-drug import provision. Investors should keep an eye on the status of the bill, because laws that hurt the drugmakers' bottom lines will hurt their stock prices as well.
The Motley Fool March 19, 2004 Bill Mann	The Drug Reimportation Disaster State-imposed pricing is not natural law. Expect Canada to have a problem supplying all those drugs.
Chemistry World November 28, 2008 Matt Wilkinson	EU claims pharma delaying tactics cost 3 billion euros Pharmaceutical manufacturers have been criticised by the EU competition commission for slowing the entry of generic medicines to the market.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool March 28, 2005 Brian Gorman	A Passage to India? Changes in India's patent law could create new dynamics for the biotech and pharmaceutical industries. Investors should be on the lookout for the firms that seek to leverage these new opportunities.
The Motley Fool March 30, 2011 Sean Williams	China Clamps Down on Drug Manufacturers These drug manufacturers could be feeling a pinch from new Chinese price caps.
The Motley Fool February 8, 2011 Brian Orelli	A Few Extra Years of Sales? Yes, Please! An EU-Canadian proposal could help drugmakers.
Chemistry World June 25, 2012	US GM Labelling Rule Quashed A US proposal that would have given individual states a mandate to set whether food manufacturers should have to communicate information about genetically modified organisms directly to consumers has been quashed by the Senate.
The Motley Fool January 22, 2007 Michael P. Cecil	Will Medicare Negotiate With Drug Companies? One of the bedrock principles of our economic system is that those buying more of a product receive a discount. Wouldn't empowering Medicare to save taxpayers' money be widely embraced as a great idea? But how would pharma investors see it?
The Motley Fool February 25, 2010 Brian Orelli	An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies.
The Motley Fool March 24, 2009 Robert Steyer	Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed.
The Motley Fool January 26, 2011 Brian Orelli	Health-Care Reform Lives: Here's Where to Invest State of the Union turned investment thesis regarding health insurance companies.
The Motley Fool January 7, 2010 Brian Orelli	Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered.
The Motley Fool May 7, 2004 Brian Gorman	CVS Fuels the Drug Debate Thomas Ryan, the CEO of CVS, supports reimporting drugs from Canada before Congress. Drugs from European companies may actually have a greater impact on price.
The Motley Fool May 18, 2010 Brian Orelli	Price Inflation in Check? Not in This Industry. Drug prices are on the rise. For now.
The Motley Fool July 30, 2010 Brian Orelli	On the Path to a Blockbuster Amgen's Prolia will be a blockbuster. Eventually.
The Motley Fool August 3, 2011 Brian Orelli	Ignore Pfizer's Financials for Now It's the pipeline that matters.
The Motley Fool December 9, 2009 Brian Orelli	Welcome to Club Biogeneric, Pfizer! The megadrugmaker jumps on the biogeneric bandwagon.
The Motley Fool November 22, 2005 Brian Gorman	Saying No to Drugs Britain's policy of restricting drug access based on cost-benefit analyses should be on the radar screen of pharmaceutical investors.
BusinessWeek May 3, 2004 John Carey	Is Reimporting Drugs A Cheap Fix? Not Really Why reimporting drugs from Canada won't work in the long run
The Motley Fool October 27, 2011 Eric Bleeker	Here's Where Pfizer's Finding Its Growth Let's examine where Pfizer's sales and earnings come from and how its sales abroad have changed over time.
The Motley Fool August 4, 2006 Selena Maranjian	Hooray for Big Pharma! There may actually be an upside to expensive pharmaceuticals. Invest in healthy, growing companies, and while you're forking over $100 for some pills, you may also be receiving $150 in dividends!
The Motley Fool March 4, 2011 Brian Orelli	Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors.
The Motley Fool May 21, 2010 Brian Orelli	Abbott Learns to Say "Low Margin" in Hindi No matter what country, overpaying isn't a good idea.
The Motley Fool December 13, 2004 Brian Gorman	Which Medications Are Your Best Bets? Consumer Reports' effort to rate drugs offers a marketing lesson to pharmaceutical companies.
The Motley Fool December 3, 2009 Brian Orelli	Health-Care Reform Is Very Taxing On the industries that keep us alive.
The Motley Fool October 15, 2009 Brian Orelli	An Ode to Wyeth Pfizer weds Wyeth today and the WYE ticker will be gone forever.
InternetNews October 13, 2004 Roy Mark	Report: The Internet and Drugs Don't Mix It seems an increasing number of Americans are researching drugs online, but safety fears chill buying.
The Motley Fool April 14, 2005 Brian Gorman	Novartis Moves on Multiple Fronts Even with its investment in a potential blockbuster, Novartis remains remarkably diversified. Investors can rest assured, though, that the company's strategy won't leave it as vulnerable as other outfits.
The Motley Fool August 28, 2009 Brian Orelli	Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug.
The Motley Fool March 30, 2011 Brian Orelli	How to Play the Pfizer Breakup (If It Happens) The sum of the parts could be worth more than the whole.
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool March 22, 2010 Brian Orelli	Health-Care Reform Passes! Here's Where to Invest Now Some healthy suggestions for your portfolio.
The Motley Fool August 25, 2006 Brian Gorman	California's Drug Demands As the pressure grows on drugmakers from legislation, growth and consolidation in the outsourcing business seem likely.
The Motley Fool September 3, 2009 Brian Orelli	Now That's How to Grow a Company! Dear Pfizer and Merck, you really should take note of how Abbott Labs is growing.
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
BusinessWeek May 20, 2009 Maria Bartiromo	Pfizer's Kindler on Health-Care Reform and the Wyeth Deal Pfizer's CEO discusses its acquisition of Wyeth and its plan to provide some drugs for free to those without jobs and insurance.
Pharmaceutical Executive May 1, 2007 Peter Pitts	Opinion: Are Price Controls the New Black? A revamped version of an old bill calling for drug importation is on the congressional runway. With bipartisan backing and red-hot Rahmed-up rhetoric, the legislation might just pass -- and spell failure for the future of innovative drug development.
The Motley Fool May 21, 2010 Brian Orelli	And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too.
The Motley Fool May 17, 2004 Roger Nusbaum	Diagnosing Pfizer Can Pfizer, the pharmaceutical company, outperform the market?
The Motley Fool January 26, 2010 Brian Orelli	Timing Is Everything for Amgen Amgen is counting on osteoporosis drug Prolia for a successful 2010.
The Motley Fool August 23, 2004 Ben McClure	Rethinking Big Pharma Risk is knocking Big Pharma stocks down. They won't be getting up anytime soon. Competition, soaring R&D costs, shifting business models, and political meddling combine to make drug stocks a riskier place to invest.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool May 20, 2008 Brian Orelli	Is Google's Newest Offering a Healthy Investment? Having all your medical records in one place is a good idea, but will people use Google Health?
The Motley Fool March 15, 2007 Brian Lawler	It's All Good for Drugmakers With the whole drug industry growing so strongly, those looking for a safe place to park their investing dollars would be smart to take a look at some of the largest generic drugmakers.